25 Gy in 5 fractions for Glioblastoma
Study Summary
This trial is comparing two radiation schedules with temozolomide chemo-radiotherapy for glioblastoma patients.
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Is this research pioneering in its methodology?
"In 2002, Schering-Plough initiated the first research trial for 25 Gy in 5 fractions. Subsequently, it was approved and granted Phase 2 drug approval after the 60 patient study concluded. Currently there are 207 active trials with 935 cities across 36 countries contributing to this large sample size."
How is 25 Gy in 5 fractions typically administered to treat medical conditions?
"25 Gray administered in 5 separate treatments is a common way to manage nitrosourea treatment. Additionally, the same protocol can be used for various other cases including refractory neuroblastoma and advanced mycosis fungoides."
Could you provide insight into prior investigations on 25 Gy in 5 fractions?
"At present, 207 clinical trials are underway searching for the efficacy of 25 Gy in 5 fractions. Of these studies, 24 are currently in phase 3 and mostly based around Seoul-Songpa; however, there is a total of 4752 sites that have operations related to this treatment running."
How many participants is this trial accommodating?
"Affirmative. According to the information presented on clinicaltrials.gov, this medical trial is still recruiting participants having been initially posted in December 2021 and last updated in January 2022. 40 individuals are needed for testing at one site."
Are there remaining opportunities for individuals to join this experiment?
"This clinical research study, which was initially advertised on 14th December 2021, is currently seeking participants. The last update to this trial's information occurred on 6th January 2022."